Susan M. Stalnecker Named to Bioventus Board of Managers DURHAM, NC – October 25, 2018 – Bioventus, a global leader in orthobiologic solutions, today [...]

Bioventus Receives ANVISA Approval to Market DUROLANE® in Brazil and Selects Pfizer as Exclusive Distribution Partner HOOFDDORP, THE NETHERLANDS – Oct [...]

Bioventus Enters Into Definitive Agreement to Divest BMP Development Program to Viscogliosi Brothers, LLC DURHAM, NC – July 23, 2018 – Bioventus, a gl [...]

Bioventus Launches DUROLANE® in the US DURHAM, NC - March 5, 2018 – Bioventus, a global leader in orthobiologic solutions, today launched DUROLANE, it [...]

Bioventus to Co-Develop Next Generation Bone Allograft with LifeLink DURHAM, NC – February 26, 2018 – Bioventus, a global leader in orthobiologic solu [...]

Bioventus to Continue Distributing SUPARTZ FX™ Through 2028 DURHAM, NC - February 12, 2018 – Bioventus, a global leader in orthobiologic solutions, ha [...]

Additional Strategic Funding for CartiHeal's Ongoing AGILI-C™ IDE Clinical Study $2.5M boost by Bioventus brings latest investment round to $21M KFAR [...]

Bioventus Launches New Website for EXOGEN® DURHAM, NC– January 25, 2018 – Bioventus, a global leader in orthobiologics, today has launched a new versi [...]

Bioventus Announces First Patients Enrolled in BONES Study for EXOGEN® Durham, NC– September 13, 2017 – Bioventus, a global leader in orthobiologics, [...]

Bioventus Receives US FDA Approval for DUROLANE® Durham, NC- September 5, 2017 – Bioventus, a global leader in orthobiologic solutions, today announce [...]